Skip to main content

Table 1 The intravenous taurolidine treatment did not impair the above mentioned blood parameters after 39 cycles (Wilcoxon test, p = not significant).

From: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case

Serum parameters

Median

Range

CA 72-4 (tumor marker, U/ml)

0.6

0.3–1.8

CEA (tumor marker, μg/l)

18.8

6.7–32.4

Leukocyte (/μl)

6.4

4.8–13.0

Hemoglobin (g/l)

13.0

10.4–14.8

Hemocrit (%)

40

32–44

Thrombocyte (103/μl)

225

171–321

Glucose (mg/dl)

94

54–283

Saline (mg/dl)

138

130–149

Potassium (mg/dl)

4.3

3.6–5.3

Creatinine (mg/dl)

1.1

0.74–1.75

Urea (mg/dl)

34

22–72

Protein (g/dl)

7.2

6.1–7.4

GOT (U/l)

23

7–95

GPT (U/l)

13

8–73

Total bilirubine (mg/dl)

0.3

0.1–0.6

Alkaline phosphatase (U/l)

70

56–122

Amylase (U/l)

53

44–104

Lipase (U/l)

17.5

17–18

INR

1.1

1.0–1.2